Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Nerigliatin (PF-04937319) in Japanese Patients with Type 2 Diabetes
NCT02292433Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jan 2015
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nerigliatin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs), Number of Participants With Protocol Defined Hypoglycaemic Adverse Events (HAEs) and 12 more. Started Jan 2015; status: completed.
02
Drugs
nerigliatin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02292433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02292433.